Publicacións nas que colabora con Jesús María Prieto Valtueña (23)

2019

  1. Liver Expression of a MiniATP7B Gene Results in Long-Term Restoration of Copper Homeostasis in a Wilson Disease Model in Mice

    Hepatology, Vol. 70, Núm. 1, pp. 108-126

2017

  1. Phase 1–2 pilot clinical trial in patients with decompensated liver cirrhosis treated with bone marrow–derived endothelial progenitor cells

    Translational Research, Vol. 188, pp. 80-91.e2

2014

  1. A quick and efficient method to generate mammalian stable cell lines based on a novel inducible alphavirus DNA/RNA layered system

    Cellular and Molecular Life Sciences, Vol. 71, Núm. 23, pp. 4637-4651

  2. Short-term intratumoral interleukin-12 expressed from an alphaviral vector is sufficient to induce an efficient antitumoral response against spontaneous hepatocellular carcinomas

    Human Gene Therapy, Vol. 25, Núm. 2, pp. 132-143

2011

  1. Treatment of chronic viral hepatitis in woodchucks by prolonged intrahepatic expression of Interleukin-12

    Journal of Virology

2010

  1. A novel system for the production of high levels of functional human therapeutic proteins in stable cells with a Semliki Forest virus noncytopathic vector

    New Biotechnology, Vol. 27, Núm. 2, pp. 138-148

2009

  1. Semliki forest virus expressing interleukin-12 induces antiviral and antitumoral responses in woodchucks with chronic viral hepatitis and hepatocellular carcinoma

    Journal of Virology, Vol. 83, Núm. 23, pp. 12266-12278

  2. Treatment of chronic viral hepatitis in woodchucks by prolonged intrahepatic expression of interleukin-12

    Journal of Virology, Vol. 83, Núm. 6, pp. 2663-2674

2008

  1. Development of a new noncytopathic Semliki Forest virus vector providing high expression levels and stability

    Virology, Vol. 376, Núm. 1, pp. 242-251

2007

  1. Biodistribution and tumor infectivity of Semliki Forest virus vectors in mice: Effects of re-administration

    Molecular Therapy, Vol. 15, Núm. 12, pp. 2164-2171

  2. Multipotent Adult Progenitor Cells (MAPC) contribute to hepatocarcinoma neovasculature

    Biochemical and Biophysical Research Communications, Vol. 364, Núm. 1, pp. 92-99

2006

  1. Increased efficacy and safety in the treatment of experimental liver cancer with a novel adenovirus-alphavirus hybrid vector

    Cancer Research, Vol. 66, Núm. 3, pp. 1620-1629

2005

  1. Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas

    Molecular Therapy, Vol. 12, Núm. 1, pp. 153-163

2003

  1. A recombinant adenovirus encoding hepatitis C virus core and E1 proteins protects mice against cytokine-induced liver damage

    Hepatology, Vol. 37, Núm. 2, pp. 461-470

  2. CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells with IFN-γ-Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination

    Journal of Immunology, Vol. 171, Núm. 11, pp. 5931-5939

  3. Engineering Th determinants for efficient priming of humoral and cytotoxic T cell responses

    International Immunology, Vol. 15, Núm. 6, pp. 691-699

  4. Potentiation of Therapeutic Immune Responses against Malignancies with Monoclonal Antibodies

    Clinical Cancer Research, Vol. 9, Núm. 15, pp. 5454-5464

2002

  1. Abnormal priming of CD4+ T cells by dendritic cells expressing hepatitis C virus core and E1 proteins

    Journal of Virology, Vol. 76, Núm. 10, pp. 5062-5070

2001

  1. Characterization of an immunologically conserved epitope from hepatitis C virus E2 glycoprotein recognized by HLA-A2 restricted cytotoxic T lymphocytes

    Journal of Hepatology, Vol. 34, Núm. 2, pp. 321-329

  2. Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity

    European Journal of Immunology, Vol. 31, Núm. 6, pp. 1780-1789